Search results
Results from the WOW.Com Content Network
Survodutide (BI 456906) is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin .
2740 14652 Ensembl ENSG00000112164 ENSMUSG00000024027 UniProt P43220 O35659 RefSeq (mRNA) NM_002062 NM_021332 RefSeq (protein) NP_002053 NP_067307 Location (UCSC) Chr 6: 39.05 – 39.09 Mb Chr 17: 31.12 – 31.16 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and ...
The private company plans to start enrollments for the trial of the drug, survodutide, which it co-invented with Danish biotech company Zealand Pharma, before the end of the year. The trials will ...
In a phase 2 trial of people who were overweight or had obesity, Boehringer Ingelheim’s survodutide, which uses both GLP-1 and glucagon, led to weight loss of 19% at 46 weeks. Another phase 2 ...
Survodutide is unique because it uses a mechanism of action (the GLP-1 receptor) that partially overlaps with the products on the market made by Eli Lilly and Novo Nordisk, but it also targets the ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
German drugmaker Boehringer Ingelheim said it hopes that drug candidate survodutide, co-developed to treat obesity and fatty liver with Zealand Pharma, could be launched in 2027 or 2028 ...
Bromovinyluracil (BVU) Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU.